Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy.
Journal
European journal of rheumatology
ISSN: 2147-9720
Titre abrégé: Eur J Rheumatol
Pays: Turkey
ID NLM: 101656068
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
22
06
2018
accepted:
15
09
2018
pubmed:
9
11
2018
medline:
9
11
2018
entrez:
9
11
2018
Statut:
ppublish
Résumé
The blockade of inflammatory mediators produced by biological therapies is associated with an increased risk of opportunistic infections, as for example Mycobacterium tuberculosis (MT). Given the endemic situation of tuberculosis (TB) in some countries and immunosuppression/anergy of patients with chronic inflammatory arthritis, we wonder whether it is necessary to monitor the MT infection after starting the biological treatment. To evaluate the frequency of the tuberculin skin test (TST) conversion and its association with an active TB infection and other disease variables. Patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and spondyloarthritis (SpA) receiving treatment with anti-TNF, tocilizumab, and/or abatacept agents were included into the study. Patients had to have a negative TST (<5 mm) at the baseline, and a second TST was performed 2-22 months after the initiation of biologic therapy. The TST conversion was considered as a variation ≥5 mm between the two TSTs performed within an interval between 2 months and 2 years. A total of 85 patients were included into the study, and 78.8% were women, with a median schooling duration of 12 years. A total of 74.1% of patients had RA, 16.5% psoriatic arthritis, and 4.7% AIJ and ankylosing spondylitis. Regarding treatment, 75.3% received anti-TNF therapy (31.8% etanercept, 21.2% adalimumab, 17.6% infliximab, 3.5% golimumab, and 1.2% certolizumab), 15.3% tocilizumab, and 9.4% abatacept. Eight patients (9.4%) developed a TST conversion. The shift was more frequent in men (62.5%) than in women (37.5%) (p=0.009), and in those with a prolonged disease duration (X 226±109 vs X130±105 [p=0.017]). This association remained after adjusting for other variables. All patients who developed a TST conversion received prophylactic isoniazid, and only one patient with other risk factors developed active TB. The frequency of a TST conversion in patients with chronic inflammatory arthritis was low and was associated with male gender and longer disease duration.
Identifiants
pubmed: 30407165
pii: eurjrheum.2018.18096
doi: 10.5152/eurjrheum.2018.18096
pmc: PMC6459330
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19-22Références
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Clin Infect Dis. 2004 May 1;38(9):1261-5
pubmed: 15127338
Ann Rheum Dis. 2005 Sep;64(9):1360-1
pubmed: 16100342
Arthritis Rheum. 2005 Nov;52(11):3403-12
pubmed: 16255017
Arthritis Rheum. 2006 Aug;54(8):2368-76
pubmed: 16868999
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
J Clin Rheumatol. 2004 Jun;10(3):110-5
pubmed: 17043481
Arthritis Rheum. 2007 Jun 15;57(5):756-61
pubmed: 17530674
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
J Rheumatol. 2009 Sep;36(9):2029-32
pubmed: 19648302
J Rheumatol. 2009 Oct;36(10):2158-63
pubmed: 19723901
Ann Rheum Dis. 2010 Sep;69(9):1589-95
pubmed: 20699242
Ann Rheum Dis. 2011 Jan;70(1):25-31
pubmed: 21109520
Cell. 1989 Mar 10;56(5):731-40
pubmed: 2647299
Clin Rheumatol. 2017 Feb;36(2):457-461
pubmed: 27817127
Acta Clin Croat. 2017 Jun;56(2):203-209
pubmed: 29485786
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Arch Dermatol. 1983 Nov;119(11):934-45
pubmed: 6639116
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570
Am J Respir Crit Care Med. 1999 Jan;159(1):15-21
pubmed: 9872812